A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of CVN058 on Mismatch Negativity in Subjects With Stable Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs CVN-058 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Cerevance
- 24 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 24 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.